Research Article

The Association of Thyrotropin and Autoimmune Thyroid Disease in Developing Papillary Thyroid Cancer

Table 4

Univariate analysis: related variables in patients with papillary thyroid cancer excluding those with Graves’ disease who received thyroidectomy.

ResultBenign ()PTC () value

Gender, female (%)221 (84.0)126 (87.5)0.346
Age (years)49.2 ± 14.547.2 ± 12.90.165
BMI (kg/m2)23.9 ± 3.624.1 ± 4.10.638
TSH (mIU/L)1.9 ± 5.151.9 ± 1.40.975
TSH with group0.003
        (i) Group 1 (<0.14)19 (10.6)3 (2.5)
       (ii) Group 2 (0.14–1.04)64 (35.8)29 (24.2)
      (iii) Group 3 (1.04–1.92)48 (26.8)46 (38.3)
      (iv) Group 4 (>1.92)48 (26.8)42 (35.0)
FT4 (ng/dl)1.3 ± 0.521.2 ± 0.20.130
T4 (μg/dl)8.9 ± 10.67.4 ± 1.20.445
T3 (ng/dl)106.9 ± 40.7106.5 ± 21.90.955
Anti-TPO Ab positive (%)18 (15.9)22 (26.8)0.063
Anti-Tg Ab positive (%)4 (8.9)11 (17.2)0.219
TRAb positive (%)7 (24.1)2 (9.5)0.192
MicroPTC (%)26 (18.1)
Stage1101 (70.1)
211 (7.6)
311 (7.6)
421 (14.6)
LN metastasis (%)46 (31.9)
Synchronous nonthyroidal malignancies or tumors (%)19 (13.2)

PTC: papillary thyroid cancer; BMI: body mass index; TSH: thyroid-stimulating hormone; FT4: free thyroxine; T4: thyroxine; T3: triiodothyronine; anti-TPO Ab: thyroid peroxidase antibodies; anti-TG Ab: antithyroglobulin antibody; TRAb: TSH receptor antibody; HT: Hashimoto’s thyroiditis; microPTC: papillary thyroid microcarcinoma; LN: lymph node.